Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
Solid Tumor Market: By Tumor Type, By Therapy Type, By Drug Class, By Route of Administration By End Users, and Region Forecast 2020-2031
Solid Tumor Market size was valued at US$ 4,832.3 million in 2024 and is projected to reach US$ 5,589.0 million by 2031 at a CAGR of 2.1% from 2025-2031. Moreover, the U.S. Solid Tumor Market is projected to grow significantly, reaching an estimated value of US$ 1,743.8 Million by 2031. The market focuses on the diagnosis, treatment, and management of solid tumors, which are abnormal masses of tissue that do not contain liquid or cyst areas.
The market is being primarily driven by the rising global cancer burden, particularly in high-incidence cancers like breast, lung, colorectal, and prostate. Aging populations, lifestyle risk factors, and improved diagnostic access have led to a growing patient pool, prompting increased investments in early detection, targeted therapies, and precision oncology. A major trend shaping the market is the integration of advanced diagnostics, especially liquid biopsies and AI-powered tools, which enable early detection, real-time monitoring, and personalized treatment decisions. These innovations are redefining clinical workflows and accelerating the shift toward data-driven, individualized care.
Expansion of immuno-oncology into early-stage cancers and new tumor types, supported by growing approvals for checkpoint inhibitors, ADCs, and tumor-agnostic drugs provides opportunity for the market. Additionally, biosimilars, mRNA cancer vaccines, and digital therapeutics are creating new growth avenues. However, high treatment costs remain a major restraint, limiting access, especially in low- and middle-income countries. Even in developed markets, cost-effectiveness concerns impact reimbursement and adoption. Other challenges include limited biomarker infrastructure and disparities in oncology workforce distribution. Despite these barriers, the market’s trajectory remains positive, propelled by innovation, policy support, and the urgent need for effective cancer solutions.
Based on the tumor type
Based on tumor type, the malignant tumor segment holds the largest market share in the market. This is primarily due to the high prevalence of cancers such as breast, lung, colorectal, and prostate, which are classified as malignant and often require extensive treatment involving surgery, chemotherapy, radiotherapy, and targeted therapies. The rising global cancer burden, along with advancements in diagnostics and oncology drugs, further drives the dominance of this segment. On the other hand, benign tumors, though common, typically do not pose immediate life-threatening risks and require less aggressive treatment, resulting in a comparatively smaller market share.
Based on the therapy type
Based on therapy type, targeted therapy holds the largest market share in the market due to its high efficacy, reduced side effects, and growing use across major cancers like breast, lung, and colorectal. Targeted therapies, including monoclonal antibodies and small molecules, are designed to interfere with specific molecular targets driving tumor growth, making them essential in precision oncology. Drugs like trastuzumab (HER2+ breast cancer) and osimertinib (EGFR-mutated NSCLC) have become standard-of-care treatments. Hedgehog pathway inhibitors represent the smallest market segment, largely due to their limited indications (e.g., basal cell carcinoma) and narrow patient base.
Based on the drug class
Based on drug class, monoclonal antibodies hold the largest market share in the market due to their targeted mechanism of action, proven clinical efficacy, and broad application across multiple high-incidence cancers such as breast, lung, and colorectal. These biologics offer greater specificity and fewer off-target effects compared to traditional chemotherapeutic agents, making them a preferred choice in modern oncology. Blockbuster drugs like trastuzumab (Herceptin), bevacizumab (Avastin), and pembrolizumab (Keytruda) have set the benchmark for monoclonal antibody success in solid tumors. In contrast, proteasome inhibitors, primarily used in hematologic malignancies, hold the smallest share in the solid tumor segment due to their limited approval and modest results in solid tumor indications.
Based on the route of administration
Based on the route of administration, parenteral administration holds the largest market share in the global solid tumor market. Most monoclonal antibodies, chemotherapies, and immunotherapies are administered intravenously or subcutaneously in clinical settings to ensure precise dosing, rapid action, and controlled bioavailability, especially for aggressive or advanced-stage cancers. Hospital infrastructure and infusion centers are well-equipped for parenteral regimens, which are preferred in both first-line and combination therapies. However, the oral segment is steadily growing due to patient preference for convenience and better compliance, particularly with targeted therapies and tyrosine kinase inhibitors, though it still accounts for a smaller overall share.
Based on the end users
Based on end users, hospitals hold the largest market share in the global solid tumor market due to their comprehensive oncology infrastructure, availability of multidisciplinary care, and ability to administer complex treatments such as parenteral chemotherapy, immunotherapy, and advanced diagnostics. Hospitals are the primary setting for cancer diagnosis, surgery, infusion therapies, and clinical trials, making them central to solid tumor management. They also serve as referral centers for severe and late-stage cases requiring intensive care. While specialty clinics are expanding in urban areas with outpatient services and targeted therapies, and home care is gaining traction for oral medications and palliative care, these segments still hold a smaller share compared to hospital-based oncology care.
Study Period
2025-2031Base Year
2024CAGR
2.1%Largest Market
North-AmericaFastest Growing Market
Asia-Pacific
One key driver of the market is the increasing global cancer burden, particularly the rising incidence of solid tumors such as breast, lung, colorectal, and prostate cancers. With aging populations, sedentary lifestyles, rising tobacco and alcohol use, and exposure to environmental carcinogens, the number of diagnosed cancer cases continues to grow, driving demand for diagnostics, targeted therapies, and advanced oncology treatments. This surge in patient volume compels healthcare systems and pharmaceutical companies to invest in early detection technologies and next-generation treatments such as immunotherapies, monoclonal antibodies, and precision medicine. Additionally, expanding health insurance coverage in emerging markets and growing patient awareness are accelerating treatment adoption. While the rising cancer incidence remains the primary growth engine, other contributing drivers include advancements in tumor biology research, approvals of novel biologics and biosimilars, increasing investments in oncology clinical trials, and the integration of artificial intelligence in oncology diagnostics and personalized therapy planning.
A prominent restraint in the market is the high cost of advanced therapies, particularly immunotherapies, targeted biologics, and precision diagnostics. These treatments, while clinically effective, can cost hundreds of thousands of dollars per patient annually, creating affordability challenges for both patients and healthcare systems. This financial burden is especially pronounced in low- and middle-income countries, where limited insurance coverage and constrained public healthcare budgets restrict access. Even in developed markets, payers are increasingly scrutinizing cost-effectiveness, often delaying or limiting reimbursement. High R&D costs, complex manufacturing (especially for biologics), and regulatory hurdles further inflate prices. As a result, many promising therapies face slow adoption despite clinical success. While pricing remains the central restraint, additional barriers include disparities in biomarker testing infrastructure, shortage of trained oncologists in rural regions, and the risk of immune-related adverse events, which can lead to treatment discontinuation or increased hospitalization, impacting both clinical outcomes and market penetration.
One key opportunity in the market lies in the expansion of immuno-oncology therapies into early-stage and multiple solid tumor types. Initially approved for metastatic cancers, immune checkpoint inhibitors like pembrolizumab and nivolumab are now being evaluated, and increasingly approved, for adjuvant and neoadjuvant use in earlier stages of cancers such as non-small cell lung cancer (NSCLC), melanoma, and bladder cancer. This broadens the eligible patient base and significantly increases market potential. Pharmaceutical companies are accelerating clinical trials exploring combinations of immunotherapy with chemotherapy, radiation, and novel agents like antibody-drug conjugates (ADCs) to improve outcomes in solid tumors. Furthermore, approvals of tumor-agnostic treatments (e.g., for NTRK or MSI-H mutations) open doors for broader applications across rare and difficult-to-treat cancers. While this expanding role of immunotherapy forms the core opportunity, other promising areas include biosimilars of key biologics, emerging markets adoption, mRNA-based cancer vaccines, and digital therapeutics that enhance treatment adherence and outcomes.
The most significant current trend in the market is the rapid integration of advanced diagnostics, particularly liquid biopsies and AI-driven tools, which enable precision treatment and real-time disease monitoring. Liquid biopsies that detect circulating tumor DNA (ctDNA) are gaining ground for early detection, minimal residual disease (MRD) monitoring, and relapse prediction, often identifying recurrences up to two years before imaging. Coupled with this, AI-powered imaging and genomics platforms are transforming diagnostic accuracy and treatment planning. Next-generation sequencing (NGS) panels and molecular profiling integrated with AI tools are enabling clinicians to match patients to targeted or immune-oncology therapies more effectively. For example, ASCO 2025 highlighted ctDNA liquid biopsies for lung and breast cancer, and AI tools for prostate cancer patient selection. Meanwhile, innovations in immuno-oncology (e.g., ADCs, CAR?T, mRNA vaccines) and the approval of tumor-agnostic therapies are complementing diagnostic advances. These trends collectively signal a shift toward personalized, data-driven care in solid tumor management.
Report Benchmarks |
Details |
Report Study Period |
2025-2031 |
Market Size in 2024 |
US$ 4,832.3 million |
Market Size in 2031 |
US$ 5,589.0 million |
Market CAGR |
2.1% |
By Tumor Type |
|
By Therapy Type |
|
By Drug Class |
|
By Route of Administration |
|
By End User |
|
By Region |
|
According to a PBI Analyst, the market is witnessing robust growth driven by rising cancer incidence, increased adoption of targeted therapies, and rapid advancements in diagnostics like liquid biopsy and AI-powered genomics. Immuno-oncology is expanding beyond metastatic settings into early-stage treatments, unlocking significant market potential. However, high therapy costs and access disparities in low- and middle-income countries remain key challenges. Regulatory support, growing biosimilar entry, and digital health integration are helping to balance innovation with affordability. Overall, the market is transitioning toward personalized, precision-based care, offering strong investment opportunities across diagnostics, biologics, and combination treatment pipelines for the years ahead.
Download Free Sample Report
Solid tumor market size was valued at US$ 4,832.3 million in 2024 and is projected to reach US$ 5,589.0 million by 2031 at a CAGR of 2.1% from 2025-2031.
Rising global cancer incidence and the shift to targeted and immuno-oncology therapies are primary growth drivers.
Targeted therapies dominate due to high efficacy and wide applicability in common solid tumors.
Market is segmented based on tumor type, therapy type, drug class, route of administration, end use, and region.
North America dominates the market due to the strong R&D, early adoption of advanced treatments, and robust healthcare infrastructure.
1.Executive Summary |
2.Global Solid Tumor Market Introduction |
2.1.Global Solid Tumor Market - Taxonomy |
2.2.Global Solid Tumor Market - Definitions |
2.2.1.Tumor Type |
2.2.2.Therapy Type |
2.2.3.Drug Class |
2.2.4.Route of Administration |
2.2.5.Region |
3.Global Solid Tumor Market Dynamics |
3.1. Drivers |
3.2. Restraints |
3.3. Opportunities/Unmet Needs of the Market |
3.4. Trends |
3.5. Product Landscape |
3.6. New Product Launches |
3.7. Impact of COVID 19 on Market |
4.Global Solid Tumor Market Analysis, 2020 - 2024 and Forecast 2025 - 2031 |
4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
4.3. Market Opportunity Analysis |
5.Global Solid Tumor Market By Tumor Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
5.1. Benign Tumor |
5.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.1.3. Market Opportunity Analysis |
5.2. Malignant Tumor |
5.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
5.2.3. Market Opportunity Analysis |
6.Global Solid Tumor Market By Therapy Type, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
6.1. Chemotherapy |
6.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.1.3. Market Opportunity Analysis |
6.2. Immunotherapy |
6.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.2.3. Market Opportunity Analysis |
6.3. Targeted Therapy |
6.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.3.3. Market Opportunity Analysis |
6.4. Tyrosine kinase inhibitors |
6.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.4.3. Market Opportunity Analysis |
6.5. Proteasome inhibitor |
6.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.5.3. Market Opportunity Analysis |
6.6. Hedgehog pathway inhibitor |
6.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.6.3. Market Opportunity Analysis |
6.7. Others |
6.7.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
6.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
6.7.3. Market Opportunity Analysis |
7.Global Solid Tumor Market By Drug Class, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
7.1. Alkylating Agents |
7.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.1.3. Market Opportunity Analysis |
7.2. Antimetabolites |
7.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.2.3. Market Opportunity Analysis |
7.3. Topoisomerase Inhibitors |
7.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.3.3. Market Opportunity Analysis |
7.4. Proteasome Inhibitors |
7.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.4.3. Market Opportunity Analysis |
7.5. Monoclonal Antibodies |
7.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.5.3. Market Opportunity Analysis |
7.6. Others |
7.6.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
7.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
7.6.3. Market Opportunity Analysis |
8.Global Solid Tumor Market By Route of Administration, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
8.1. Oral |
8.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.1.3. Market Opportunity Analysis |
8.2. Parenteral |
8.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.2.3. Market Opportunity Analysis |
8.3. Others |
8.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
8.3.3. Market Opportunity Analysis |
9.Global Solid Tumor Market By Region, 2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
9.1. North America |
9.1.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.1.3. Market Opportunity Analysis |
9.2. Europe |
9.2.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.2.3. Market Opportunity Analysis |
9.3. Asia Pacific (APAC) |
9.3.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.3.3. Market Opportunity Analysis |
9.4. Middle East and Africa (MEA) |
9.4.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.4.3. Market Opportunity Analysis |
9.5. Latin America |
9.5.1. Market Analysis, 2020 - 2024 and Forecast, 2025 - 2031, (Sales Value USD Million) |
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
9.5.3. Market Opportunity Analysis |
10.North America Solid Tumor Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
10.1. Tumor Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.1.1.Benign Tumor |
10.1.2.Malignant Tumor |
10.2. Therapy Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.2.1.Chemotherapy |
10.2.2.Immunotherapy |
10.2.3.Targeted Therapy |
10.2.4.Tyrosine kinase inhibitors |
10.2.5.Proteasome inhibitor |
10.2.6.Hedgehog pathway inhibitor |
10.2.7.Others |
10.3. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.3.1.Alkylating Agents |
10.3.2.Antimetabolites |
10.3.3.Topoisomerase Inhibitors |
10.3.4.Proteasome Inhibitors |
10.3.5.Monoclonal Antibodies |
10.3.6.Others |
10.4. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.4.1.Oral |
10.4.2.Parenteral |
10.4.3.Others |
10.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
10.5.1.United States of America (USA) |
10.5.2.Canada |
11.Europe Solid Tumor Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
11.1. Tumor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.1.1.Benign Tumor |
11.1.2.Malignant Tumor |
11.2. Therapy Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.2.1.Chemotherapy |
11.2.2.Immunotherapy |
11.2.3.Targeted Therapy |
11.2.4.Tyrosine kinase inhibitors |
11.2.5.Proteasome inhibitor |
11.2.6.Hedgehog pathway inhibitor |
11.2.7.Others |
11.3. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.3.1.Alkylating Agents |
11.3.2.Antimetabolites |
11.3.3.Topoisomerase Inhibitors |
11.3.4.Proteasome Inhibitors |
11.3.5.Monoclonal Antibodies |
11.3.6.Others |
11.4. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.4.1.Oral |
11.4.2.Parenteral |
11.4.3.Others |
11.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
11.5.1.Germany |
11.5.2.France |
11.5.3.Italy |
11.5.4.United Kingdom (UK) |
11.5.5.Spain |
12.Asia Pacific (APAC) Solid Tumor Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
12.1. Tumor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.1.1.Benign Tumor |
12.1.2.Malignant Tumor |
12.2. Therapy Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.2.1.Chemotherapy |
12.2.2.Immunotherapy |
12.2.3.Targeted Therapy |
12.2.4.Tyrosine kinase inhibitors |
12.2.5.Proteasome inhibitor |
12.2.6.Hedgehog pathway inhibitor |
12.2.7.Others |
12.3. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.3.1.Alkylating Agents |
12.3.2.Antimetabolites |
12.3.3.Topoisomerase Inhibitors |
12.3.4.Proteasome Inhibitors |
12.3.5.Monoclonal Antibodies |
12.3.6.Others |
12.4. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.4.1.Oral |
12.4.2.Parenteral |
12.4.3.Others |
12.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
12.5.1.China |
12.5.2.India |
12.5.3.Australia and New Zealand (ANZ) |
12.5.4.Japan |
12.5.5.Rest of APAC |
13.Middle East and Africa (MEA) Solid Tumor Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
13.1. Tumor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.1.1.Benign Tumor |
13.1.2.Malignant Tumor |
13.2. Therapy Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.2.1.Chemotherapy |
13.2.2.Immunotherapy |
13.2.3.Targeted Therapy |
13.2.4.Tyrosine kinase inhibitors |
13.2.5.Proteasome inhibitor |
13.2.6.Hedgehog pathway inhibitor |
13.2.7.Others |
13.3. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.3.1.Alkylating Agents |
13.3.2.Antimetabolites |
13.3.3.Topoisomerase Inhibitors |
13.3.4.Proteasome Inhibitors |
13.3.5.Monoclonal Antibodies |
13.3.6.Others |
13.4. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.4.1.Oral |
13.4.2.Parenteral |
13.4.3.Others |
13.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
13.5.1.GCC Countries |
13.5.2.South Africa |
13.5.3.Rest of MEA |
14.Latin America Solid Tumor Market ,2020 - 2024 and Forecast 2025 - 2031 (Sales Value USD Million) |
14.1. Tumor Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.1.1.Benign Tumor |
14.1.2.Malignant Tumor |
14.2. Therapy Type Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.2.1.Chemotherapy |
14.2.2.Immunotherapy |
14.2.3.Targeted Therapy |
14.2.4.Tyrosine kinase inhibitors |
14.2.5.Proteasome inhibitor |
14.2.6.Hedgehog pathway inhibitor |
14.2.7.Others |
14.3. Drug Class Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.3.1.Alkylating Agents |
14.3.2.Antimetabolites |
14.3.3.Topoisomerase Inhibitors |
14.3.4.Proteasome Inhibitors |
14.3.5.Monoclonal Antibodies |
14.3.6.Others |
14.4. Route of Administration Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.4.1.Oral |
14.4.2.Parenteral |
14.4.3.Others |
14.5. Country Analysis 2020 - 2024 and Forecast 2025 - 2031 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
14.5.1.Brazil |
14.5.2.Mexico |
14.5.3.Rest of LA |
15. Competition Landscape |
15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
15.2.1.Abbott Laboratories Inc. |
15.2.2.Biogen Inc. |
15.2.3.AstraZeneca PLC |
15.2.4.Boehringer Ingelheim GmbH |
15.2.5.Amgen Inc. |
15.2.6.Bristol-Myers Squibb Company |
15.2.7.Stemline Therapeutics, Inc. |
15.2.8.Baxter International Inc. |
15.2.9.Eli Lilly and Company |
15.2.10.GlaxoSmithKline PLC |
15.2.11.Hoffmann-La Roche AG |
16. Research Methodology |
17. Appendix and Abbreviations |
Key Market Players